Rapamycin as a potential treatment for Alzheimer’s disease

A drug that has been touted to help you live as long as possible may be the key to treating Alzheimer’s. Rapamycin as a potential treatment for Alzheimer’s disease has been eyed by scientists, who are now investigating

Full story:


Cognitive and memory issues are a big part of why I started on Rapamycin. I have noticed significant improvement in those areas since I’ve been on Rapa, though I have no numbers to back that up.

My mother has been diagnosed with Alzheimer’s and I am going to try to get her on it too. Her memory issues are very pronounced.


I am in my wife’s Hybrid Prius going to the gym… and NPR is on the radio… shakes my head.

And, an ad comes on the radio station for the Missouri Flagship - Big 10 University of Missouri Columbia. They are seeking clinical trial - looking for healthy people age 45 to 65 to test sirolimus for memory benefits. They pay you $1,000. You can call to participate: (573) 884-5372
Also here is a link to the website to learm more about Ai-Ling Lin, PhD: linbrain.com/clinical-trial

Maybe some here are interested. Here is a video explains what they test for your potential to have Alzehiemers… for participants. Link: Paul Pepper: Prof. Ai-Ling Lin, Alzheimer's Research Study & Lois Long, Missouri Haiku Project | KBIA Scroll down for video.

MU professor of radiology AI-LING LIN is looking for healthy people, aged 45-65, to participate in a research study that hopes to answer the question: “will sirolimus treatment improve MRI measures of brain function in individuals with a genetic predisposition to Alzheimer’s disease.”


I received a call from MU Professor of Radiology AI-LING LIN, I had left my number.

She was pleased to learn that I have been on Rapamycin for 3 years with no side effects and my personal observations of improved memory.

She is hoping to get 40 healthy participants for her initial study on rapamycin and increased blood flow and afterwards expand the trial. Ultimately focused on prevention and improvement of alzheimer’s in people.

Told her about rapamycin.news
She was unaware of our group. Happy to learn there is a group self experimenting with few negative side effects.

Was pleased to hear her hypothesis of rapamycin seemed on the right track.

I will try to recruit a few participants from our bioscience faculty.


Great to hear of the study. Please keep us in the loop!

Research Description

Dr. Lin is an expert on translational neuroimaging of brain vascular and metabolic function in aging, Alzheimer’s disease, stroke and traumatic brain injury. She developed and applied magnetic resonance imaging and spectroscopy and positron emission tomography to test nutritional and pharmacologic approaches for protecting the brain from aging, traumatic brain injury, and Alzheimer’s disease. She also has applied artificial intelligence to identify markers that are highly predictable for Alzheimer’s disease development and progression and applied gut microbiome analyses to study gut-brain interaction underlying Alzheimer’s disease.



This just out, Alzheimer’s related to inflammation and cell (neuron - nerve cell) corruption from immune response.

Two things we think are addressed by rapamycin… immunity enhancement and reduction in inflammation.



This is the stuff I love to read. Keep it coming! :slight_smile:

I find this interesting… we obvously need to carefully balance the interest in following the higher dose mice trials that suggest higher dose equate to longer lifespan improvement, and lower doses that may give great immunity enhancement.

I think that this balance is the key issue, and difficult to do given the lack of data and issue that few of us track our immune system function as we ideally would (i.e. via monitoring TREGS , as Dudley Lamming has suggested).


I found this part of this podcast interesting with John Kastelein regarding the potential protection apoA1 has for people with APOE4 Alzheimer’s alleles:

But the CETP inhibitors are interesting as well, and I like what he said earlier(55:00 - 1:08:00), we don’t need PCSK9, nor CETP. According to him CETP deficiency is linked with a longevity, decrease in Alzheimer’s etc. They are studying the possible first working CETP inhibitor.


Obicetrapib is a novel, selective CETP inhibitor that potently decreases low-density lipoprotein-cholesterol (LDL-C) as well as increases high-density lipoprotein-cholesterol (HDL-C) and the number of ApoA1-containing lipoproteins.

In July 2021, we reported positive results from a Phase 2 study of oral obicetrapib demonstrating over 50% LDL-lowering as an adjunct to high-intensity statins showing that an oral dose of obicetrapib could potentially address substantial unmet need for patients whose LDL-C levels and cardiovascular risk remain too high despite being treated. Additionally, clinical data from the study showed the genetic mechanism of CETP as an LDL-lowering mechanism, supporting NewAmsterdam’s strategy for developing obicetrapib in metabolic diseases and other major diseases of high unmet need. As of July 2022, NewAmsterdam has initiated all three of its planned phase 3 trials: BROADWAY, BROOKLYN, and PREVAIL.